Zogenix to Present at Two Upcoming Conferences
SAN DIEGO, Nov 21, 2011 (GlobeNewswire via COMTEX) --
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that Roger L. Hawley, Chief Executive Officer, and Ann Rhoads, Executive Vice President and Chief Financial Officer, will be presenting at two upcoming institutional investor conferences.
The first conference is the Leerink Swann Management Access Day on November 22, 2011 in Boston, MA. This conference will allow institutional investors to meet with Mr. Hawley and Ms. Rhoads but does not include a formal presentation.
Event: Leerink Swann Management Access Day Date: Tuesday, November 22, 2011 Place: Boston, MA
The second conference is the Piper Jaffray Health Care Conference on November 29, 2011 in New York, NY. The presentation will be webcast live and archived for 90 days on Zogenix' Investor Relations website at ir.zogenix.com. Mr. Hawley and Ms. Rhoads will also be available to participate in one-on-one meetings at the conference.
Piper Jaffray Healthcare Event: Conference Date: Tuesday, November 29, 2011 Place: New York, NY Time: 3:00 pm ET
Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL(R) DosePro(R) (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead product candidate, Zohydro(TM) (hydrocodone bitartrate), is a novel, oral, single-entity (without acetaminophen) extended-release capsule formulation currently in Phase 3 clinical trials for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix's second DosePro product candidate, Relday(TM), is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia.
This news release was distributed by GlobeNewswire, www.globenewswire.com
CONTACT: INVESTORS: Zack Kubow The Ruth Group 646.536.7020 email@example.com MEDIA: Victoria Aguiar The Ruth Group 646.536.7013 firstname.lastname@example.org